Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Ronald E. Rose"'
Autor:
Ronald E. Rose, Dennis Hernandez, Paul J. Falk, Karen Ericson, Nannan Zhou, Alexandra Thiry, Fiona McPhee
Publikováno v:
Hepatology Communications, Vol 2, Iss 9, Pp 1123-1135 (2018)
Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutio
Externí odkaz:
https://doaj.org/article/f6a89167bb844b3781c6aa86a855821f
Autor:
Paul Falk, Alexandra Thiry, Fiona McPhee, Ronald E. Rose, Karen Ericson, Dennis Hernandez, Nannan Zhou
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 9, Pp 1123-1135 (2018)
Hepatology Communications, Vol 2, Iss 9, Pp 1123-1135 (2018)
Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6439e4a8688ba3c64c928457bdd80a8d
https://doi.org/10.1002/hep4.1231
https://doi.org/10.1002/hep4.1231
Autor:
Carl J Baldick, Michael J Wichroski, Annapurna Pendri, Ann W Walsh, Jie Fang, Charles E Mazzucco, Kevin A Pokornowski, Ronald E Rose, Betsy J Eggers, Mayla Hsu, Weixu Zhai, Guangzhi Zhai, Samuel W Gerritz, Michael A Poss, Nicholas A Meanwell, Mark I Cockett, Daniel J Tenney
Publikováno v:
PLoS Pathogens, Vol 6, Iss 9, p e1001086 (2010)
Small molecule inhibitors of hepatitis C virus (HCV) are being developed to complement or replace treatments with pegylated interferons and ribavirin, which have poor response rates and significant side effects. Resistance to these inhibitors emerges
Externí odkaz:
https://doaj.org/article/1ee8b0be7b894e5398d932dbcf2e4866
Autor:
Jie Fang, Carl J. Baldick, Bernadette Kienzle, Richard J. Colonno, Ann W. Walsh, Steven Levine, Charles E. Mazzucco, Kevin A. Pokornowski, Daniel J. Tenney, Ronald E. Rose, Michael Wichroski
Publikováno v:
Antimicrobial Agents and Chemotherapy. 53:2762-2772
Amino acid substitutions that confer reduced susceptibility to antivirals arise spontaneously through error-prone viral polymerases and are selected as a result of antiviral therapy. Resistance substitutions first emerge in a fraction of the circulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ea3655561ff4a3203889e86ae8e0645
https://doi.org/10.1128/aac.00130-09
https://doi.org/10.1128/aac.00130-09
Autor:
Betsy J. Eggers, Cheng-Fang Yu, Carl J. Baldick, Steven Levine, Jie Fang, Daniel J. Tenney, Ronald E. Rose, Richard J. Colonno, Kevin A. Pokornowski
Publikováno v:
Journal of Hepatology. 48:895-902
Background/Aims The efficacy of anti-viral therapy for chronic hepatitis B virus (HBV) is lost upon the emergence of resistant virus. Using >500 patient HBV isolates from several entecavir clinical trials, we show that phenotypic susceptibility corre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcdb214df8b90b48ab3631ce3c108aa5
https://doi.org/10.1016/j.jhep.2007.12.024
https://doi.org/10.1016/j.jhep.2007.12.024
Autor:
Ronald E. Rose, Michael Wittekind, David R. Langley, Jacques Friborg, Kevin Kish, Qi Guo, Valentina Goldfarb, Herbert E. Klei, Pin-Fang M. Lin, Yaqun Zhang, Steven Sheriff
Publikováno v:
Journal of Virology. 81:9525-9535
Atazanavir, which is marketed as REYATAZ, is the first human immunodeficiency virus type 1 (HIV-1) protease inhibitor approved for once-daily administration. As previously reported, atazanavir offers improved inhibitory profiles against several commo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af8c3c24fb58201b14d92ea4dbf9029b
https://doi.org/10.1128/jvi.02503-05
https://doi.org/10.1128/jvi.02503-05
Autor:
Jie Fang, Ronald E. Rose, Ann W. Walsh, Steven Levine, Mayla Hsu, Joanna Yang, Betsy J. Eggers, Charles E. Mazzucco, Richard J. Colonno, Mary Jane Plym, Sharon Zhang, Carl J. Baldick, Daniel J. Tenney, Patricia Poundstone, Kevin A. Pokornowski, Cheng-Fang Yu
Publikováno v:
Antimicrobial Agents and Chemotherapy. 51:902-911
Entecavir (ETV) is a deoxyguanosine analog approved for use for the treatment of chronic infection with wild-type and lamivudine-resistant (LVDr) hepatitis B virus (HBV). In LVD-refractory patients, 1.0 mg ETV suppressed HBV DNA levels to below the l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df3809379905ca949eb5306c86d4312
https://doi.org/10.1128/aac.00833-06
https://doi.org/10.1128/aac.00833-06
Autor:
Jie Fang, Mary Jane Plym, Kevin A. Pokornowski, Daniel J. Tenney, Mayla Hsu, Betsy J. Eggers, Charles E. Mazzucco, Cheng F. Yu, Sharon Zhang, Carl J. Baldick, K. Klesczewski, Ronald E. Rose, Richard J. Colonno, Ann W. Walsh, Steven Levine
Publikováno v:
Hepatology. 44:1656-1665
Comprehensive monitoring of genotypic and phenotypic antiviral resistance was performed on 673 entecavir (ETV)-treated nucleoside naïve hepatitis B virus (HBV) patients. ETV reduced HBV DNA levels to undetectable by PCR (300 copies/mL,57 IU/mL) in 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b93b3a763eae5cadf592d7076825c50
https://doi.org/10.1002/hep.21422
https://doi.org/10.1002/hep.21422
Autor:
Joseph Yanchunas, Ronald E. Rose, Jacques Friborg, Li Tao, Richard J. Colonno, David R. Langley, Michael L. Doyle
Publikováno v:
Antimicrobial Agents and Chemotherapy. 49:3825-3832
Protease inhibitors (PIs) are highly effective drugs against the human immunodeficiency virus (HIV), yet long-term therapeutic use is limited by emergence of HIV type 1 (HIV-1) protease substitutions that confer cross-resistance to multiple protease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4e7adf9cf71ad29001f396172581f4
https://doi.org/10.1128/aac.49.9.3825-3832.2005
https://doi.org/10.1128/aac.49.9.3825-3832.2005
Autor:
Donald R. O'Boyle, Ronald E. Rose, Robert A. Fridell, Mengping Liu, Richard J. Colonno, Julie A. Lemm, Min Gao
Publikováno v:
Intervirology. 48:183-191
Objective: To utilize chimeric hepatitis C virus (HCV) replicons to select adaptive mutation(s) that allow replication of a genotype 1a replicon. Methods: We used a genetic approach to gradually apply selective pressure by generating chimeric replico
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9daee718c9790abfdc507db25179a935
https://doi.org/10.1159/000081747
https://doi.org/10.1159/000081747